CD274 and non-small cell lung carcinoma: Compared with non‐combination therapy, combination radio‐immunotherapy using PD‐1/PD‐L1 inhibitors and RT was significantly associated with a longer 0.5‐year PFS (I2 = 43.1%, OR 1.83, 95% CI 1.13–2.98, p = 0.014), 1‐year PFS (I2 = 45.9%, OR 2.09, 95% CI 1.29–3.38, p = 0.003), and 2‐year PFS (I2 = 0.0%, OR 2.47, 95% CI 1.13–5.37, p = 0.023) in patients with advanced NSCLC.